AlphAIAlphAI — Financial news for AI agents
prnewswire.comSEP 92 min read$RSSS

Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results

Research Solutions (RSSS) reported fiscal Q4 2026 revenue of $12.1M, down from $12.4M YoY. Full-year revenue was $48.3M, slightly below prior year's $49.1M. Net income rose to $2.8M for the year, up from $1.3M. B2B ARR grew 14% YoY to $16.2M, with AI-related ARR up 125% sequentially. Gross margin improved to 53% in Q4 and 51.9% for the year, driven by platform revenue growth.

Original reporting
prnewswire.com
Published Sep 9, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results — source image
Source · prnewswire.com
Decision brief

The 30-second read

$RSSSBullishMed
01

Why it matters

The earnings release provides fresh data on profitability and ARR growth, offering traders a basis for short‑term positioning.

02

Market read

First‑report earnings with improved net income and ARR may drive short‑term price movement for RSSS.

03

What to watch

Higher operating expenses and lower cash flow from operations may constrain near‑term growth.

Relevance 7/10Novelty 7/10Timing: post‑earnings release today

Background

Research Solutions, Inc. (NASDAQ:RSSS) provides an AI‑powered research workflow platform. The FY2026 results were released via a PRNewswire press release.

Company-level read

Ticker impact

$RSSSBullishHigh confidence
Context

Research Solutions reported FY2026 financial results, including net income of $2.8M and ARR of $22.5M, marking the first public disclosure of these figures.

Expected impact

Potential modest upside as investors digest improved profitability and AI-driven ARR growth.

Evidence & confidence

First-time earnings release with better-than-expected net income and ARR expansion signals operational improvement.

Market effects

Sector

Positive signal for AI‑enabled research platforms may benefit peer SaaS and AI service providers.

Regional

U.S. tech sector may see modest uplift.

Global

Limited to niche AI SaaS market.

Counterpoint

What could challenge this read

Revenue decline and cash flow pressure could limit upside; investors may remain cautious.

Key entities

  • Executive
    Roy W. Olivier

    President and CEO of Research Solutions, quoted on AI product launches and strategic M&A plans.

Read at source← All news

Related articles

SEP 9
$RSSSMed

Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results

Research Solutions, Inc. (RSSS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Research Solutions Reports Fourth Quarter and Fiscal Year 2026 Results Reports Record Fiscal Year Net Income of $2.8 Million, 14% YoY B2B ARR Increase and ARR of $22.5 Million HENDERSON, Nev., September 9, 2026 — Research Solutions, Inc. (NASDAQ

SEC EDGAR 8-K2 min
NOV 3
$TLNMed

Talen Energy Q3 Earnings Call Highlights

Talen Energy (TLN) reported Q3 updates, including 70% hedging for 2027 and 35% for 2028. It raised 2028 adjusted free cash flow per-share outlook to $48 (midpoint) and initiated 2029 guidance of $46-$50. The company increased share repurchase authorization to $3B by 2028. Talen expects $6B in cumulative adjusted free cash flow through 2029 and supports PJM market reforms.

finance.yahoo.com7 min
NOV 3
$MDGLMed

What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Call

Madrigal Pharmaceuticals (MDGL) reported Q3 net income of $55.4M, up from a $114.2M loss last year. The company expects sequential growth in Q4 and is expanding its commercial outreach. Madrigal is advancing its F4c MASH development program, with trial results expected in late 2027. The company plans to initiate three Phase II combination trials in 2027 and presented real-world data at a liver disease meeting.

finance.yahoo.com7 min
NOV 3
$KDPMedAI 8/10

Keurig Dr Pepper Q3 Earnings Call Highlights

Keurig Dr Pepper (KDP) reported Q3 earnings, highlighting 2.7% U.S. Coffee sales growth despite consumer value pressures. GHOST energy drink surpassed 10% market share, and Electrolit grew 40%. KDP launched the Keurig Alta system. JDE Peet's exceeded expectations, contributing $2.6B in net sales. KDP raised JDE Peet's EPS outlook but lowered legacy KDP growth expectations. The company plans to use $780M from asset sales for debt repayment and reaffirmed its 2026 sales outlook.

finance.yahoo.com7 min